Halozyme Therapeutics (HALO) Return on Invested Capital (2016 - 2026)

Halozyme Therapeutics (HALO) has 10 years of Return on Invested Capital data on file, last reported at 0.0% in Q1 2026.

• On a quarterly basis, Return on Invested Capital changed N/A year-over-year to 0.0% in Q1 2026; TTM through Mar 2026 was 0.0%, a N/A change from a year earlier, with the FY2022 full-year figure at 0.04%, up 2.0% from the prior year.
• Return on Invested Capital for Q1 2026 stood at 0.0%, down from 0.0% in the prior quarter.
• Over the last five years, Return on Invested Capital for HALO reached as high as 0.12% in Q3 2023 and fell as low as 0.0% in Q1 2026.
• Historically, Return on Invested Capital has averaged 0.02% across 4 years, with a median of 0.01% in 2022.
• Across the five-year window, Return on Invested Capital changed 0 bps in 2022 and gained 12 bps in 2023, its largest moves.
• Year by year, Return on Invested Capital stood at 0.01% in 2022, then jumped by 1349 bps to 0.12% in 2023, then sank by 96 bps to 0.0% in 2025, then dropped by 3 bps to 0.0% in 2026.
• Per Business Quant data, the three most recent Return on Invested Capital figures were 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.12% in Q3 2023.